OKLO Shares Slide as Analysts Slash Targets Following Earnings Miss
Oklo Inc. (OKLO) shares are plunging 4.76% to $54.00 in Thursday's session as the market continues to digest a wider-than-expected quarterly loss and a wave of analyst price target cuts. Despite recent regulatory milestones for its isotope business, investor sentiment has soured following disclosures of significant insider selling and a projected acceleration in cash burn for the 2026 fiscal year.
Earnings Miss and Analyst De-Rating
Oklo Inc. is facing a wave of selling pressure today, with the stock falling significantly more than the broader S&P 500. The primary catalyst is the fallout from the company's Q4 2025 earnings report, which revealed a loss per share of $0.27—significantly wider than the $0.17 loss anticipated by Wall Street. While Oklo remains a pre-revenue company, the 58% miss on the bottom line has forced analysts to re-evaluate the stock's near-term valuation.
Following the report, several major investment banks aggressively lowered their price targets. The Goldman Sachs Group slashed its target from $91.00 to $65.00, maintaining a Neutral rating, while Citigroup lowered its outlook to $73.50. B. Riley Financial also trimmed its target to $92.00. These revisions reflect growing concern over the company's capital intensity; Oklo guided for a massive 2026 cash deployment between $350 million and $450 million to fund its reactor pilot programs and isotope facilities.
Insider Selling and Regulatory Mixed Signals
Adding to the downward momentum are recent SEC filings showing substantial insider selling by the company's top leadership. CEO Jacob DeWitte and CFO Richard Craig Bealmear both disclosed sales of approximately 72,000 shares each, totaling over $8.6 million in combined transactions. While some of these sales were reportedly related to tax obligations from vested units, the timing—coinciding with the earnings miss—has rattled retail and institutional investors alike.
Ironically, the sell-off comes despite what would normally be considered positive regulatory news. Earlier this week, Oklo's subsidiary, Atomic Alchemy, received its first materials license from the Nuclear Regulatory Commission (NRC) to handle and process isotopes. Additionally, the Department of Energy (DOE) approved Nuclear Safety Design Agreements for the Aurora reactor pilot in Idaho. However, the market appears to be discounting these long-term milestones in favor of immediate financial concerns, particularly as the company pushed its target for nuclear heat production at the Idaho National Laboratory out to 2028.
Sector Competition and Market Context
Oklo's decline is also occurring against a backdrop of high-profile activity in the Small Modular Reactor (SMR) space. Competitor NuScale Power (SMR) announced a major strategic partnership with Ebara Elliott Energy this morning, and X-energy signed a letter of intent with Talen Energy for a gigawatt-scale deployment. This competitive pressure, combined with a 0.50% dip in the SPY, has left OKLO vulnerable as capital rotates toward peers with more immediate commercial catalysts.
With 2.4 million shares changing hands today, volume is elevated as the stock tests support levels near the $54.00 mark. Investors are now looking toward the mid-2026 target for the Groves test reactor criticality as the next major hurdle to prove the company's execution capabilities.
Key Takeaways
- Oklo reported a Q4 loss of $0.27 per share, missing consensus estimates of $0.17 and signaling higher-than-expected operational costs.
- Major institutions including Goldman Sachs and Citi slashed price targets, citing a projected 2026 cash burn of up to $450 million.
- Disclosures of multi-million dollar stock sales by the CEO and CFO have weighed heavily on investor sentiment during the post-earnings drift.
- Regulatory wins from the NRC and DOE were overshadowed by the company's adjusted timeline for its first operational reactor in Idaho.